Organovo (NASDAQ:ONVO) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Organovo (NASDAQ:ONVO) in a note issued to investors on Thursday. The firm set a “sell” rating on the medical research company’s stock.

Organovo Stock Performance

Shares of NASDAQ ONVO opened at $2.74 on Thursday. Organovo has a 52-week low of $2.63 and a 52-week high of $21.96. The stock has a market cap of $4.66 million, a P/E ratio of -3.22 and a beta of 0.45. The firm has a 50 day moving average price of $5.01 and a 200 day moving average price of $5.15.

Organovo (NASDAQ:ONVO) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($2.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.52) by $0.24. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.05 million. Organovo had a negative net margin of 10,151.64% and a negative return on equity of 346.26%. Analysts predict that Organovo will post -0.77 earnings per share for the current fiscal year.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.